Acasti Pharma Free Cash Flow 2014-2023 | ACST

Acasti Pharma free cash flow from 2014 to 2023. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
Acasti Pharma Annual Free Cash Flow
2023 -15.93
2022 -17.23
2021 -14.39
2020 -23.27
2019 -25.32
2018 -10.12
2017 -6.65
2016 -5.26
2015 -6.44
2015
2014 -6.53
2014
2013 -2.55
2013
Acasti Pharma Quarterly Free Cash Flow
2023-12-31 -10.14
2023-09-30 -8.24
2023-06-30 -6.24
2023-03-31 -15.93
2022-12-31 -12.60
2022-09-30 -8.87
2022-06-30 -5.43
2022-03-31 -17.23
2021-12-31 -14.09
2021-09-30 -9.51
2021-06-30 -3.40
2021-03-31 -14.39
2020-12-31 -12.63
2020-09-30 -8.41
2020-06-30 -4.21
2020-03-31 -23.27
2019-12-31 -20.34
2019-09-30 -12.98
2019-06-30 -6.84
2019-03-31 -25.32
2018-12-31 -17.30
2018-09-30 -9.74
2018-06-30 -4.59
2018-03-31 -10.12
2017-12-31 -6.55
2017-09-30 -3.11
2017-06-30 -1.30
2017-02-28 -6.65
2016-11-30 -4.94
2016-08-31 -3.11
2016-05-31 -1.99
2016-03-31 -5.25
2016-02-29
2015-12-31 -3.85
2015-09-30 -2.64
2015-06-30 -0.87
2015-03-31 -6.44
2014-12-31 -4.12
2014-09-30 -2.19
2014-06-30 -0.45
2014-03-31 -6.53
2014-02-28
2013-12-31 -2.00
2013-09-30 -1.17
2013-06-30 -0.92
2013-03-31 -2.55
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.027B $0.000B
Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti's only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $15.482B 5.59
Dr Reddy's Laboratories (RDY) India $12.441B 19.67
Aspen Pharmacare (APNHY) South Africa $5.038B 0.00
BridgeBio Pharma (BBIO) United States $4.375B 0.00
Bausch Health Cos (BHC) Canada $3.183B 2.48
Amphastar Pharmaceuticals (AMPH) United States $2.009B 13.75
Supernus Pharmaceuticals (SUPN) United States $1.646B 0.00
Taysha Gene Therapies (TSHA) United States $0.447B 0.00
Generation Bio (GBIO) United States $0.193B 0.00
Assembly Biosciences (ASMB) United States $0.069B 0.00
Personalis (PSNL) United States $0.064B 0.00
Sol-Gel Technologies (SLGL) Israel $0.025B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00